PIK3CD and asthma: Moreover, several phase I or phase 2 clinical trials have been performed using dual p110δ/p110γ inhibitors, including IPI-145 (phase 2a involving mild asthma subjects; NCT01653756) and RV-1729 (phase 1 involving healthy volunteers; NCT01813084 and NCT02140320) [95].